Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Purchases Majority Stake In Australian Biotech Arana, Clearing Way For Full-scale Acquisition

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Through ongoing buying of shares in the target company, Cephalon International Holdings has achieved a controlling 50 percent-plus interest in Australian biotech Arana. Cephalon's offer to acquire Arana is now "free from all outstanding conditions," Cephalon announced May 20

You may also be interested in...



Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary

PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary

Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary

PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary

Recent Biotech Financings: Xanodyne, Avid, Cephalon, And Proteon

Cash isn’t easy to come by, but financing is available for public and private biotechs, at the right price.

Related Content

UsernamePublicRestriction

Register

SC071689

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel